Latest / CME Outfitters Medical Education / Webcast: CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes
Transcript
- 0:01SPEAKER_04: Hello, and welcome to a special summary presentation of the CIDP masterclass Early Diagnosis, Emerging Options, and Better Outcomes.
- 0:13SPEAKER_04: My name is Dr.
- 0:15SPEAKER_04: Ariel Marks, and today's program will reprise key presentations and a case study roundup from the live Echo series held between January and June of 2026.
- 0:29SPEAKER_04: This activity is provided by Boston University, Chabanian and Abadisian School of Medicine, and CME Outfitters.
- 0:38SPEAKER_04: It is supported by an independent education grant from Argenics.
- 0:44SPEAKER_04: Again, I am Dr.
- 0:45SPEAKER_04: Ariel Marks.
- 0:46SPEAKER_04: I am the program director of the Neuromuscular Medicine Fellowship at Boston University Medical Center, and I am an assistant professor of neurology at Boston University Shabanin and Abadisian School of Medicine.
- 1:01SPEAKER_04: And I am delighted to welcome my colleagues, who I will ask to introduce themselves, starting with Rachel.
- 1:10SPEAKER_02: Thanks, Ariel.
- 1:11SPEAKER_02: Hello, I'm Dr.
- 1:12SPEAKER_02: Rachel Kaplan, and I'm an assistant professor of neurology at BU School of Medicine in Boston.
- 1:18SPEAKER_02: And now I'll toss it to Al Lorio.
- 1:21SPEAKER_00: Thanks, Rachel.
- 1:22SPEAKER_00: My name is Al Laurio.
- 1:23SPEAKER_00: I'm a pharmacy director over at New England Life Care Specialty Pharmacy in Wolburn, Massachusetts.
- 1:28SPEAKER_00: And next up is Maggie Naclario.
- 1:31SPEAKER_03: Hi, everyone.
- 1:32SPEAKER_03: Thanks, Al.
- 1:33SPEAKER_03: My name is Maggie.
- 1:34SPEAKER_03: I'm a physician associate in neuromuscular medicine in the Department of Neurology at Brigham Women's Hospital in Boston, Massachusetts.
- 1:41SPEAKER_03: Back to you, Ariel.
- 1:43SPEAKER_04: Well, thank you very much.
- 1:45SPEAKER_04: And may I say that is a pleasure and has been a privilege to work with all of you throughout our live series.
- 1:52SPEAKER_04: And I'm really happy that we have this opportunity to present this special wrap-up edition together.
- 1:58SPEAKER_04: So our learning objectives today are to assess the clinical heterogeneity and pathophysiology of CIDP, including the significance of IgG autoantibodies in its development, to utilize guideline recommended diagnostic criteria to identify patients with CIDP, to evaluate current and emerging treatment options, including limitations of standard therapies and appropriate integration of novel agents into practice, and to incorporate collaborative care strategies to enhance long-term outcomes and quality of life for individuals with CIDP.
- 2:42SPEAKER_04: So I'm going to start us off with talking about the pathophysiology and the significance of IgG at antibodies, and then the rest of our team will each take turns on presenting regarding the other learning objectives.
- 2:59SPEAKER_04: So first we're going to take a step back and do a quick rundown of the nervous system.
- 3:07SPEAKER_04: The nervous system includes the central and peripheral nervous systems and runs from the cortex down through the deep cerebral structures, the brainstem, the cerebellum, the spinal cord, and then we get down into the peripheral nervous system, and that includes the peripheral nerves, the neuromuscular junction, and the muscle.
- 3:29SPEAKER_04: And the part of the nervous system that we are focusing on for the entirety of this series where CIDP happens is in the peripheral nerves.
- 3:41SPEAKER_04: So I just thought it was really important to take that step back and put into context where in the nervous system we're even talking about.
- 3:49SPEAKER_04: We're talking about a disorder of the peripheral nerves.
- 3:53SPEAKER_04: And specifically, we're talking about an autoimmune disease of the peripheral nervous system.
- 3:59SPEAKER_04: And so the way that that happens is you can see on our slide we have a lymph node that which is where our immune system lives.
- 4:10SPEAKER_04: We have T cells and B cells, and they can get activated and cross the blood brain a barrier, or in this case, in the peripheral nervous system, the blood nerve barrier.
- 4:22SPEAKER_04: And so those autoantibodies and macrophages and T cells can enter and cross that barrier of protection and damage the peripheral nerve itself, either by destroying the myelin or by destroying the neurons and their axons themselves.
- 4:42SPEAKER_04: And here in CIDP specifically, we're going to be talking about the immune system damaging the peripheral nervous system's myelin, which are of course the protective cells that protect the neurons and allow their conduction to go as efficiently as possible.
- 5:01SPEAKER_04: And so when we talk about a chronic demyelinating autoimmune disease of the peripheral nerves, the basket of diagnoses that we're talking about is called CIDP, which stands for chronic inflammatory demyelinating polyrediculoneuropathy.
- 5:23SPEAKER_04: And again, just to disambiguate that really large-sounding word, chronic means it happens over time and needs constant uh treatment.
- 5:30SPEAKER_04: Inflammatory means autoimmune.
- 5:32SPEAKER_04: Demyelinating means it doesn't damage the neurons directly, but rather it damages the myelin primarily.
- 5:41SPEAKER_04: And then polyredicular neuropathy means it can affect lots of different nerve roots and peripheral nerves all at the same time, giving us more whole body symptoms as someone with CIDP experiences.
- 5:55SPEAKER_04: Briefly, a background of this condition, CIDP.
- 6:00SPEAKER_04: It happens in about 1 to 100,000 in the general population.
- 6:07SPEAKER_04: One out of every 100,000 folks come down with this condition.
- 6:11SPEAKER_04: Usually patients present between the ages of 40 and 60 when the disease starts.
- 6:17SPEAKER_04: And it seems to be male predominant a little bit, preferring men over women two to one, although many women come in with this condition as well.
- 6:30SPEAKER_04: And the clinical presentation, a patient will come to your clinic with progressive weakness and numbness that's happening over weeks.
- 6:39SPEAKER_04: And this is a key definition is that it happens slowly over the course of weeks to a few months and does not happen rapidly.
- 6:49SPEAKER_04: If it happens too quickly, we can be dealing with other autoimmune processes in the peripheral nervous system, but not CIDP.
- 6:57SPEAKER_04: Usually the weakness and numbness that these patients will get is more proximal than distal, so affecting their thigh muscles more than their feet, their shoulder muscles more than their hands, although that's not a hard and fast rule.
- 7:11SPEAKER_04: There usually isn't diaphragmatic involvement.
- 7:14SPEAKER_04: So thankfully, these patients don't get short of breath and don't have trouble breathing.
- 7:19SPEAKER_04: But there are many variants.
- 7:21SPEAKER_04: Some variants it can be only motor and not sensory, or vice versa.
- 7:26SPEAKER_04: Some variants it can affect the distal extremities, their hands and feet, more than the larger shoulder and hips.
- 7:34SPEAKER_04: So it can, it really is a whole basket of different presentations.
- 7:39SPEAKER_04: But that's how most patients present.
- 7:43SPEAKER_04: And the pathophysiology, as we discussed, is an auto-antibody-mediated demyelination.
- 7:49SPEAKER_04: So our immune system is attacking our myelin cells that are protecting the peripheral nerve axons.
- 8:00SPEAKER_04: CIDP, again, this is a really nice slide that shows the common distribution of weakness that these patients experience and really emphasizes that proximal more than distal weakness and numbness that folks have.
- 8:16SPEAKER_04: Although, as you can see, there are different models of uh of how patients can present.
- 8:23SPEAKER_04: Some patients can present with distal predominance as opposed to proximal.
- 8:27SPEAKER_04: The key thing, as we mentioned, is that it happens over at least eight weeks.
- 8:31SPEAKER_04: That is the definition of CIDP.
- 8:33SPEAKER_04: If it progresses over a shorter period of time than that, then these patients then your patient might have a different disease.
- 8:42SPEAKER_04: And importantly, for the diagnosis on the physical examination, the patient will not only have weakness and numbness, but they will also have reduced or even absent reflexes on their deep tendon reflex examination, as many conditions with uh of the peripheral nervous system do.
- 9:01SPEAKER_04: And we won't get into why that is the case, but that is a feature of CIDP.
- 9:07SPEAKER_04: And really the important thing to remember is this slide, which shows that CIDP is really a very complex Venn diagram of a lot of different conditions.
- 9:20SPEAKER_04: Uh it's it's it's really an umbrella of diagnoses.
- 9:23SPEAKER_04: And so the typical CIDP makes up about 50% of cases.
- 9:30SPEAKER_04: Uh, but you can also see that you know, 15% of people can present asymmetrically.
- 9:37SPEAKER_04: Some people can be sensory predominant, some people can be distal predominant, some people have a whole class of what we call paranodal antibodies that are resistant to treatment.
- 9:48SPEAKER_04: And so, because of all these differences in how they present and how they respond to treatment, it's really important to identify the subclass of CIDP and to really see CIDP as an umbrella of many different diagnoses.
- 10:03SPEAKER_04: Um, and along that line, uh uh that that notion of an umbrella of anti of diagnoses, there is a whole umbrella of antibodies that make up this condition.
- 10:13SPEAKER_04: And we don't have to read through all of these different antibodies and the things that make them different, but this is here as a resource uh an important thing to point out.
- 10:23SPEAKER_04: As we said, is that we have these uh uh the la the uh fifth and sixth ones here, the NF155 and the NF140.
- 10:31SPEAKER_04: These variants can be really resistant to typical treatments.
- 10:35SPEAKER_04: Um, the last, uh the second to last from the mag IgM antibody uh is associated with malignancy, and that person should be screened for malignancy.
- 10:44SPEAKER_04: So there are lots of different factors that need to come into play when we're diagnosing CIDP, and each of these uh specific diseases within the CIDP umbrella have different things that we need to think about when we're diagnosing.
- 11:02SPEAKER_04: Um great.
- 11:04SPEAKER_04: So uh I'm going to now hand it off to uh Dr.
- 11:08SPEAKER_04: Kaplan to discuss how we diagnose CIDP.
- 11:12SPEAKER_04: Rachel, you can take it away.
- 11:15SPEAKER_02: Okay.
- 11:16SPEAKER_02: So diagnosing CIDP is notoriously challenging, which has led to a high rate of both misdiagnosis and delayed diagnosis or underdiagnosis.
- 11:26SPEAKER_02: There's no single biomarker for CIDP, so we can't rely on a single test or scan.
- 11:33SPEAKER_02: This means that we need to do really excellent clinical evaluations, carefully rule out mimics, and look closely at whether patients are meeting the well-established diagnostic criteria.
- 11:43SPEAKER_02: And even after patients meet the criteria for a CIDP diagnosis, we should be checking at regular intervals to make sure that patients are having the response to treatment that we expect and reevaluating the diagnosis if they have a minimal or incomplete response.
- 12:00SPEAKER_02: Let's review again what CIDP looks like.
- 12:04SPEAKER_02: Over half of patients have typical CIDP.
- 12:07SPEAKER_02: Subacute or chronic progressive weakness is the major symptom.
- 12:12SPEAKER_02: Patients will have weakness that is symmetric, affecting both proximal and distal arm and leg muscles.
- 12:17SPEAKER_02: But it's very rare for them to have weakness in their extraocular muscles, facial muscles, or swallowing or breathing muscles.
- 12:26SPEAKER_02: Patients also have sensory symptoms, including tingling and numbness, and can have nerve root or radiating pain, though pain should not be the most prominent feature.
- 12:38SPEAKER_02: The minority of patients who have invariant CIDP will have one of five subtypes.
- 12:45SPEAKER_02: Multifocal CIDP, where weakness is patchy and asymmetric.
- 12:50SPEAKER_02: This used to be called MADSAM or Lewis Sumner syndrome, pure motor or pure sensory CIDP, focal CIDP, which causes weakness and sensory loss due to acquired demyelation in one limb only, and distal CIDP.
- 13:06SPEAKER_02: There is a very broad differential diagnosis for CIDP.
- 13:10SPEAKER_02: I have divided the differential diagnosis into other disorders which cause peripheral nerve demyelination, and more broadly other disorders that cause progressive generalized weakness.
- 13:22SPEAKER_02: Among other peripheral nerve demyelating disorders, other diseases that should be considered when we're doing evaluation for CIDP include the following.
- 13:33SPEAKER_02: There are the autoimmune nodopathies, which are newly described severe neuropathies, which are associated with nodal and parinodal antibodies to contactin Casper 1 and Neurofascine 155.
- 13:48SPEAKER_02: These are poorly responsive to IVIG.
- 13:52SPEAKER_02: Then there's Poeham's syndrome, a cancer-associated syndrome, which stands for peripheral neuropathy, organomegaly, endocrinopathy, M protein, and skin changes, and anti-MAG neuropathy, which has a distal CIDP phenotype and is associated with an IgM para protein and Waldenstrom's macroglobulinemia.
- 14:16SPEAKER_02: I didn't include multifocal motor neuropathy on this slide, but it is another peripheral nerve demelinating disorder that affects motor nerves only, and so should also be included in the differential diagnosis for patients with pure motor CIDP.
- 14:30SPEAKER_02: We should also make sure that we're not actually dealing with the case of an inherited demyinating neuropathies such as charcomary tooth disease, which progresses much more slowly and which is associated with foot changes like high arches and hammertose.
- 14:44SPEAKER_02: Finally, sometimes primarily axonal neuropathies like advanced diabetic neuropathy can show some secondary demyelination, leading to overdiagnosis of CIDP if these findings are over-interpreted.
- 14:58SPEAKER_02: Other disorders that cause progressive weakness and or sensory loss include ALS, inclusion body myositis, neuro lymphomatosis, subacute combined degeneration due to B12 deficiency, and toxic and metabolic neuropathies and ganglionopathies, as well as polyridiculopathies, can present with progressive weakness and sensory loss and potentially look a lot like CIDP, especially before nerve conduction studies are completed.
- 15:32SPEAKER_02: A study of a few dozen patients referred to a tertiary care center for care of refractory CIDP, found that a large number of them actually had different disorders, including ALS, inclusion body myositis, and even functional neurological disorder.
- 15:50SPEAKER_02: When we're doing our clinical history and exam, we need to ask the patient about the rate and progression of weakness and sensory loss, the presence and quality of pain, the degree of disability, and whether there were any preceding events such as inciting injuries or infections.
- 16:07SPEAKER_02: On our examination, we should be examining the patient for weakness in ocular, facial, neck, and limb muscles, especially looking for facial or ocular weakness that could sway us more towards an alternative diagnosis from CIDP.
- 16:25SPEAKER_02: We should examine for sensory loss to all modalities and examine the reflexes to make sure that they fit the criteria of hypo or a reflexia.
- 16:34SPEAKER_02: And we should also check for muscle atrophy, fasciculations, ataxia, or tremor, all of which would be red flags that this might be something other than CIDP.
- 16:46SPEAKER_02: When doing our laboratory evaluation with EMG and nerve conduction studies, this is really a key part of the diagnosis of CIDP.
- 16:55SPEAKER_02: According to experts of CIDP, electrodiagnostic testing is mandatory to establish this diagnosis.
- 17:02SPEAKER_02: And the use of European Academy of Neurology diagnostic criteria is critical to establish that this is a primary demyelinating disorder.
- 17:13SPEAKER_02: Overinterpretation of slight demyelinating findings, like slightly slowed nerve conduction velocity and diabetics, for instance, is one of the most common sources of misdiagnosis.
- 17:24SPEAKER_02: And so these guidelines are really important to making sure that we don't make that kind of a mistake.
- 17:30SPEAKER_02: If electrodiagnostic criteria are met in a patient who clinically has typical CIDP, no further workup is required for diagnosis.
- 17:41SPEAKER_02: However, if there's any diagnostic ambiguity, we can try and evaluate for other CIDP mimics.
- 17:48SPEAKER_02: There's serum testing, checking for diabetes, checking for HIV if the patient is at high risk, checking in all patients with CIDP a serum protein electrophoresis and immunopexation to rule out a paraprotonemic neuropathy.
- 18:05SPEAKER_02: If the patient has a distal CIDP phenotype, the DADS or DADS neuropathy, we should send for an anti-MAG antibody.
- 18:14SPEAKER_02: And then finally checking nodal and perinodal antibodies in cases of IVIG refractory CIDP or especially severe CIDP.
- 18:26SPEAKER_02: CSF testing plays a role if electrodiagnostic criteria aren't fully met.
- 18:32SPEAKER_02: For example, if we see changes that are primary demyelating but limited to only one nerve.
- 18:38SPEAKER_02: And then MRI and neuromuscular ultrasound might additionally show nerve or nerve root enlargement that can be a tip-off for demyelinating neuropathy.
- 18:50SPEAKER_02: Genetic testing has a role if we're uncertain whether the patient could have a genetic demyelinating neuropathy such as CMT type 1.
- 19:02SPEAKER_02: So when we have patients with CIDP, we have to follow them doing objective assessments to see if they're responding to therapy.
- 19:12SPEAKER_02: This includes using scores such as the NCAT score and the IROD score to measure disability, doing strength testing with objective manual muscle testing as well as grip strength dynamometry.
- 19:26SPEAKER_02: And then we can do testing of GATE as well as questionnaires to measure the quality of life and how that's responding to treatment.
- 19:35SPEAKER_02: This ensures that we are tracking our patients' improvement to IVIG versus not.
- 19:44SPEAKER_02: And if the patients are not responding to therapy, to then carefully reconsider other differential diagnoses.
- 19:50SPEAKER_04: Thank you so much, Rachel, for your great presentation.
- 19:53SPEAKER_04: So I'll start the conver uh the conventional and historic uh treatments, and then Al is going to present separately on the new and emerging treatments.
- 20:02SPEAKER_04: So, first, uh an overview of the historical treatments.
- 20:06SPEAKER_04: So the mainstay of historical treatments has been steroids, uh immunoglobulins, or plasma exchange, and then other immunomodulatory therapies, which have classically included azithioprene, uh mycophenylate mofatil, and rituximab, and a couple of others.
- 20:27SPEAKER_04: Um, and then of course the novel immunomodulatory therapies, which Al will tell us about soon.
- 20:34SPEAKER_04: Uh, but first let's talk about those classic uh treatments.
- 20:39SPEAKER_04: So, steroids, uh, I wanted to talk about the evidence behind uh each of these, and steroids have been uh studied greatly for a long time.
- 20:50SPEAKER_04: And according to the Cochrane review in 2017, um there was a uh the the one of the best studies was a non-blinded uh trial.
- 21:01SPEAKER_04: So there was no placebo, it was just a control group.
- 21:05SPEAKER_04: So that's not great as far as uh allowing bias in.
- 21:09SPEAKER_04: Um and the data as presented here makes it seem uh like prednisone did much better than the control group.
- 21:19SPEAKER_04: You can see that the median uh for the control group uh who did not receive steroids uh slightly worsened over time on their neurological disability score, whereas the prednisone group improved by 10 points over the course of the study.
- 21:36SPEAKER_04: Um but again, not only was there bias in this study uh because of the lack of a placebo group, but there was also actually some missing data.
- 21:47SPEAKER_04: Uh, and so it wasn't statistically significant at the end of the day, despite what looked like good numbers here.
- 21:55SPEAKER_04: And so the Cochrane review uh felt like this study, which is One of the best studies we have as far as proof that steroids work, the the uh was very low.
- 22:07SPEAKER_04: Uh so the evidence was very low.
- 22:09SPEAKER_04: Um it doesn't mean that steroids don't work, and clinically, we all have treated patients with steroids and see that over time they do improve, but it just means that we don't have a good study to show its efficacy.
- 22:23SPEAKER_04: Um, so that might be a little bit disappointing for all of us who have been using steroids to treat these patients for a long time to find out how weak the evidence uh is.
- 22:34SPEAKER_04: Then we move on to the treatment of CIDP with IVIG, and we have a couple of uh data points that I want to talk about.
- 22:43SPEAKER_04: So, what we have here uh was a study in the LANSA in 2008.
- 22:48SPEAKER_04: Um it was a randomized controlled trial.
- 22:51SPEAKER_04: It was a response conditional crossover is the specific type of trial.
- 22:56SPEAKER_04: It included 117 patients.
- 22:59SPEAKER_04: Uh, and what the the way that they were treated was uh they were treated with the intervention group was treated with a loading dose of two grams per kilogram, and then uh received one gram per kilogram every three weeks.
- 23:13SPEAKER_04: Uh one group received this dose of IVIG, and the other group received infusions that were just placebo.
- 23:22SPEAKER_04: Um and they were judged based on their INCAT disability score, which is one of the uh grading scales that Rachel reviewed, uh, as well as grip strength, an MRC SUM score, and a couple of, you know, a couple different scores.
- 23:37SPEAKER_04: Um and uh we saw that 86% of the patients who received IVIG were considered treatment responders, and 52% of the placebo were considered treatment responders.
- 23:54SPEAKER_04: Uh so that's a big gap between the placebo and the IVIG groups.
- 24:00SPEAKER_04: Uh, and the number needed to treat was three, meaning you have to give three people IVIG in order to see a significant statistically significant improvement in one of those three people.
- 24:12SPEAKER_04: And here you can see this beautiful Kaplan Meyer curve of folks who would relapse in the uh over the period of 27 weeks, more and more of the placebo group relapsed, whereas in the IVIG group uh the relapse rate was much lower.
- 24:28SPEAKER_04: Um, so that's really solid evidence from one super well-run trial, right?
- 24:34SPEAKER_04: Unlike the steroid uh data, where there wasn't, there hasn't been a really well-run trial to really investigate the question of steroids efficacy.
- 24:43SPEAKER_04: Um there is another uh uh study that I wanted to point out, and that is this meta-analysis, uh, which was done by the Cochrane uh a Cochrane review in 2013.
- 24:58SPEAKER_04: All of this is to say that the best design studies included in this meta-analysis showed that IVIG is statistically significant as compared to placebo in all of these studies.
- 25:11SPEAKER_04: And you can see they were done in uh between 1993, 1996, 2001, 2008.
- 25:17SPEAKER_04: And so uh and so that is really powerful evidence that over and over we've proven that IVIG, in fact, is statistically significantly better than placebo and really does work.
- 25:30SPEAKER_04: I wanted to include briefly uh data showing that subcutaneous Ig also helps prevent relapse.
- 25:39SPEAKER_04: Uh, you can see from this advanced CIDP uh trial uh published only in this decade that uh this Kaplan-Meyer curve of risk of relapse goes way high in the placebo group up to 30%, whereas the subcutaneous Ig keeps these patients controlled uh and only uh less than 10% of folks relapsed.
- 26:06SPEAKER_04: And uh we can see similar findings uh uh with uh the later trial done the year after.
- 26:13SPEAKER_04: And so all of this is to say that uh subcutaneous Ig also works as an option.
- 26:20SPEAKER_04: Um plasma exchange.
- 26:22SPEAKER_04: Uh plasma exchange is essentially dialysis of large proteins as opposed to dialysis of small molecules that we're used to with hemodialysis.
- 26:31SPEAKER_04: Uh, and the idea is that by dialyzing out all of the proteins and uh the autoimmune proteins and the autoimmune antibodies that uh are damaging our nerves, we can clean out the blood.
- 26:45SPEAKER_04: So uh in this study in 1994 in the Annals of Neurology, we uh it showed definitively for the first time that plasma exchange was non-inferior to IVIG.
- 26:58SPEAKER_04: And the standard of care now is to either use IVIG or plasma exchange, and they're considered to be equally efficacious despite the uh expert opinion that many people hold that uh that plasma exchange might be better than IVIG.
- 27:15SPEAKER_04: The data shows that they are in fact equivalent.
- 27:19SPEAKER_04: Um we're gonna move on to other immunomodulatory therapies, and we're gonna talk about azothioprene.
- 27:26SPEAKER_04: There was a study that was done back in 1985 with 27 patients.
- 27:30SPEAKER_04: Again, not well designed back then.
- 27:33SPEAKER_04: Uh, it didn't show that there was a statistically significant uh difference between folks who just received prednisone versus those who received prednisone with azithioprene.
- 27:45SPEAKER_04: You can argue that the sample size was too small, that it was only done for nine months, but in the end of the day, uh the treatment with azathioprene didn't allow patients to improve in their clinical condition or uh and also didn't allow them to get off of prednisone as a disease, as a steroid-sparing agent.
- 28:05SPEAKER_04: So uh what about mycophenylate mofital, which is another great option with relatively few side effects for an immunomodulatory uh immunosuppressive drug?
- 28:16SPEAKER_04: Um, we don't have great data for this either, but there was a retrospective study uh with a very small sample size, and we saw that 30% of these patients that were studied in 2004 who had CIDP improved with mycophenylate.
- 28:34SPEAKER_04: Um it was somewhat useful for those patients uh uh as a steroid sparing agent.
- 28:43SPEAKER_04: So maybe mycophenylate mofatil has some uh evidence behind it that is useful.
- 28:50SPEAKER_04: Um and then, of course, there is rituximab, which is one of our, what we consider a big gun in immunosuppressive therapy.
- 28:58SPEAKER_04: It totally knocks out the B cell lines, the C D20, uh CD20 cell lines, uh, and stops our body completely from making uh antibodies.
- 29:09SPEAKER_04: Uh randomized control trial in 2025 had patients who were on IVIG uh start Rituximab, compared it to placebo, and then they were weaned off IVIG.
- 29:22SPEAKER_04: And drummer all, there was no statistically significant difference between the two groups.
- 29:29SPEAKER_04: There are lots of reasons why this could be the case.
- 29:32SPEAKER_04: Could it be that the patients chosen for this study were selected because they were already refractory to IVIG and uh and it was a harder-to-treat group to begin with?
- 29:43SPEAKER_04: Maybe.
- 29:44SPEAKER_04: Uh so uh even despite this data, right, it's it makes us rethink uh how efficacious is rituximab.
- 29:54SPEAKER_04: Um so this is something to consider, even though we consider it to be a really heavy-duty therapy.
- 30:01SPEAKER_04: Um last thing that I would say about this is it could also have to do with how long they were treated for.
- 30:07SPEAKER_04: And that's something that we'll come back to when we talk about our cases about how long do you need to treat someone uh when they are uh when when when they're being treated for CIDP before we expect to see an improvement.
- 30:23SPEAKER_04: So that leaves us with the novel immunomodulatory therapies, which Al is going to talk about.
- 30:29SPEAKER_04: All right, Al, why don't you uh tee us off with uh the newer drug classes?
- 30:35SPEAKER_00: Absolutely.
- 30:35SPEAKER_00: Thank you, Ariel.
- 30:37SPEAKER_00: So uh let's uh start talking about the newer uh treatment modalities we've got here.
- 30:42SPEAKER_00: Uh so we're gonna talk about FCR and receptor blockers, as well as B cell depletion therapies, complement inhibitors, and lastly IgG cleavage enzymes.
- 30:52SPEAKER_00: And of course, when we uh transition to a novel therapy, uh we'll want to have a transition plan as well as a rescue plan in place just to minimize any adverse treatment effects.
- 31:03SPEAKER_00: So we'll start off with FCRN receptor antagonists.
- 31:07SPEAKER_00: How do things work?
- 31:08SPEAKER_00: What makes them a novel therapy?
- 31:10SPEAKER_00: Uh so under uh homeostatic conditions, IgG antibodies are periodically brought into a cell and broken down within an endosome, and then those components are recycled.
- 31:21SPEAKER_00: Uh FC receptors they sit on top of the cell's surface, and the IgG antibody does have the potential to bind to that receptor.
- 31:30SPEAKER_00: And when this happens, the IgG antibody is still brought into the cell, but that degradation, the breakdown does not occur.
- 31:37SPEAKER_00: And as the endosome travels throughout the cell, uh the FC IgG antibody complex is brought back to the surface and the antibody is released back into systemic circulation.
- 31:49SPEAKER_00: Uh, the FC receptor antagonist will compete with that site.
- 31:54SPEAKER_00: So the IgG antibody will have a tougher time binding to the FC receptor and uh will uh lead to a higher percentage of breakdown of the IgG antibodies in circulation.
- 32:07SPEAKER_00: Um so the theory here and the theory behind IgG infusions as well is that aging IgG antibodies play a part in autoimmune disease like CIDP, and we want to replace them with fresh ones.
- 32:19SPEAKER_00: With IVIG infusions, we're bringing fresh IgG antibodies into circulation.
- 32:25SPEAKER_00: Or with the receptor blockers, we are forcing the breakdown of IgG antibodies.
- 32:30SPEAKER_00: So both therapies they have a similar outcome.
- 32:33SPEAKER_00: We want newer, fresher IgG antibodies in systemic circulation, uh, less likely to float around and do things they are not supposed to do.
- 32:42SPEAKER_00: Um so currently we only have one FC receptor antagonist approved for the treatment of CIDP, or F-Gurtagemod alpha hyaluronidase.
- 32:51SPEAKER_00: Uh the uh receptor blocker portion here is the F-Gartagamod alpha, while the hyaluronidase just improves the uh permeability of the subfuke tissues and allows for more rapid injection into systemic circulation.
- 33:04SPEAKER_00: It's available in two uh two uh varieties.
- 33:08SPEAKER_00: You've got a vial, uh which you can withdraw the contents and inject subcutaneously over 30 to 90 seconds.
- 33:14SPEAKER_00: It's a pretty quick infusion.
- 33:16SPEAKER_00: Also available as a pen injector, which is given over 20 to 30 seconds.
- 33:21SPEAKER_00: So quite rapid uh compared to an IVIG infusion.
- 33:25SPEAKER_00: Uh important to note here because of the way this medication works, uh, it's forcing the breakdown of IgG, allowing your body to create fresh IgG.
- 33:36SPEAKER_00: It takes a little bit longer to take effect than an IgG infusion, than an IVIG infusion.
- 33:42SPEAKER_00: So it can take up to four to six weeks uh to start to see some real benefit from this medication.
- 33:48SPEAKER_00: So it's important to consider that if you're looking at this medication as an alternate therapy to IVIG.
- 33:55SPEAKER_00: Uh next up, we'll move on to complement inhibitors.
- 33:58SPEAKER_00: Uh so really, there's only been uh Echolysmap that's been talked about in case reports, uh, so really, really not strong evidence whatsoever for complement inhibitors, which is unfortunate because it's a it's a great class of medication to look at when treating a condition like CIDP.
- 34:16SPEAKER_00: Uh that said, today we're going to focus on uh RillaPrubart, which is a complement inhibitor undergoing phase three trials right now.
- 34:24SPEAKER_00: Uh preliminary phase two data, again, that's small patient population, um, but it was pretty favorable among patients switched from a standard IgG therapy, either IV or sub Q, uh 87% of those patients improved or remained stable after 24 weeks, while 44% of patients improved beyond their standard care.
- 34:46SPEAKER_00: Um also appeared to be safe and well tolerated, albeit that was quite a small patient population.
- 34:53SPEAKER_00: So, what makes Rillapubar unique among complement inhibitors?
- 34:57SPEAKER_00: Uh, so let's quickly, very quickly go through the three complement pathways, the classical lectin and alternative.
- 35:04SPEAKER_00: The classical pathway is, of course, antibody driven, either IgG or IgM binds to an antigen, initiates an immune response.
- 35:12SPEAKER_00: The lectin pathway is not antibody driven, it's more innate.
- 35:16SPEAKER_00: Uh, Mandose binding lectin or flecoins uh bind sugars on pathogens, also initiating an immune response.
- 35:23SPEAKER_00: So think of that as your innate immune system.
- 35:25SPEAKER_00: Uh and the alternative pathway, uh, when either the lectin or the classical pathways are activated, uh, that one just amplifies the response.
- 35:34SPEAKER_00: So uh instead of uh uh inhibiting all three of those pathways like Echolismab would, uh RillaPrubart just targets the classical pathway, just one of those blocks.
- 35:46SPEAKER_00: Um and that leaves the other two intact uh with less compromise to a patient's immune system.
- 35:52SPEAKER_00: Um again, uh with RillaproBart still going under uh undergoing phase three trials, we don't really have an established dosing regimen yet for CIDP, but uh we'll hope to uh see that come about as those trials conclude.
- 36:06SPEAKER_00: Uh next, we'll look at uh B cell depletion therapies.
- 36:09SPEAKER_00: Uh, currently, as Ariel mentioned, we use Rituximab for refractory cases.
- 36:13SPEAKER_00: Uh there are some offerings on the distant horizon listed here.
- 36:17SPEAKER_00: Um it's also uh noteworthy that um none of these are also backed by clinical trial trial data currently.
- 36:25SPEAKER_00: Uh that said, there's a couple uh noteworthy bullet points associated with a couple of these medications here.
- 36:30SPEAKER_00: Uh, for instance, uh Ukralysimab, extremely long half-life, about 27 to 30 weeks or so.
- 36:37SPEAKER_00: Um, it has been dosed every six months.
- 36:39SPEAKER_00: Um, and that is also not for uh uh CIDP, of course, but uh MS and other conditions.
- 36:45SPEAKER_00: Uh tumomab itself is available also as a pen injector, uh which is always a good patient preference, uh, helps out compliance.
- 36:54SPEAKER_00: Um you don't have to book an infusion suite, etc.
- 36:59SPEAKER_00: Um B cell depleting agents, they come in two varieties, uh anti-CD20 and anti-CD19, and this just corresponds to the surface protein uh that governs the spectrum of activity.
- 37:09SPEAKER_00: Um, of course, the end point of all the uh B cell depleting therapies, we want to reduce plasma cell differentiation and antibody production.
- 37:18SPEAKER_00: Uh anti-u-CD19 agents, as we'll see a little bit later, have a wider spectrum of activity, and they directly target uh plasma blast cells, uh, while anti-CD20 agents do not.
- 37:30SPEAKER_00: Um, in any case, uh both these types of agents, cytolytic treatment is non-reversible, it will wipe out uh the B cells it binds to.
- 37:38SPEAKER_00: Um this slide here just illustrates the broader target range of the anti-CD19 agents.
- 37:45SPEAKER_00: Uh you can see they they target not only the plasma blast cells, but also the less differentiated uh pro B cells.
- 37:52SPEAKER_00: And with that wider target range, uh anti-19 uh CD19 agents uh further reduce the number of V cells in systemic circulation compared to the anti-CD20s.
- 38:03SPEAKER_00: Um rounding out our novel therapy discussion, we're gonna look at an interesting new enzyme-based therapy called emblithase, which functions as an IgG cleavage enzyme.
- 38:15SPEAKER_00: Um IgG, if you recall, is sort of Y-shaped, with the base of the Y being the FC receptor binding site.
- 38:22SPEAKER_00: Uh and this enzyme cleaves at the hinge region of that Y shape, effectively cutting it in half.
- 38:31SPEAKER_00: This completely inactivates any circulating IgG.
- 38:34SPEAKER_00: Uh, that bottom FC fragment is also inactivated, and there is no uh complement activation at all.
- 38:42SPEAKER_00: Um while we don't have any uh direct CIBP treatment data, there is a phase two trial data for uh Guillain Baret where hemlithidase intervention was compared to a large cohort of patients treated solely with IBIG.
- 38:56SPEAKER_00: Uh the amlithidase arm uh had an amlythidase initiation followed by IVIG.
- 39:04SPEAKER_00: And in that arm, uh the time to improvement with the uh amlithidase arm was about six days versus nine to fourteen days for IBIG alone.
- 39:15SPEAKER_00: Uh 30% of the amlithidase arm were walking within one week versus less than 20% for IBIG after a week.
- 39:24SPEAKER_00: And the medium time, median time to independent walking was approximately 16 days for the enlithidase arm versus about three to six weeks for IBIG alone.
- 39:35SPEAKER_00: Um so while while it's a ways off for being a treatment option for CIBP patients, um, it does offer a pretty exciting potential as a rescue drug uh for patients suffering from severe symptoms, or theoretically it could be used to kickstart a long-term therapy.
- 39:54SPEAKER_00: Um it would be easier to track sort of disease progression uh if we were to set a patient back to zero and just see how they're doing as the therapy progresses.
- 40:05SPEAKER_00: Um let's briefly discuss when to consider a novel therapy.
- 40:10SPEAKER_00: Um I always like to say it's it's if something isn't working, then let's look to fix it.
- 40:15SPEAKER_00: Uh so uh if if symptoms are not improving or getting worse, uh current regimen is too difficult to manage logistically, like uh semi VIG doses uh can span multiple days, can take almost the entire day.
- 40:29SPEAKER_00: Umfusion suite appointments are too difficult to book, too far away, too hard to get to.
- 40:35SPEAKER_00: Again, many of these patients have uh mobility restrictions.
- 40:39SPEAKER_00: Um it's and it's always advisable not to change something that's working.
- 40:44SPEAKER_00: So you you really want to make the switch if you're looking to mitigate a challenge for that particular patient.
- 40:51SPEAKER_00: Um, and when you make that change, you want to make sure the patient's gonna be uh compliant with that therapy.
- 40:56SPEAKER_00: And you want to have that first injection or infusion uh be very structured with a lot of support, uh, either at an infusion suite or in the home, if in the home, ideally with a nurse who can provide some teaching and some support.
- 41:09SPEAKER_00: Um, just for example, uh it may it might sound easy to give yourself uh a sub Q injection, might sound like a simple task, but then it ends up being more challenging than expected.
- 41:19SPEAKER_00: Doses are missed, symptoms start to present.
- 41:22SPEAKER_00: So, really, that first initial uh uh injection or infusion, uh, we really want to have a lot of support around that.
- 41:29SPEAKER_00: And after that first infusion, if all goes well and you're on your way to transitioning that patient, you really want to continue to monitor for worsening of symptoms, uh, reduce functionality in particular.
- 41:40SPEAKER_00: Um, it's probably pertinent, it might be extremely difficult to do, but get an IVIG rescue protocol in place if needed, uh, something you probably want to have in advance, um, work it out with the insurance company, get the prior offs in place, uh, just in case that that novel therapy doesn't work as expected.
- 41:59SPEAKER_00: Um, and lastly, kind of you always want to have a plan B if that novel therapy does not uh produce the desired outcome.
- 42:05SPEAKER_00: Either restarting a therapy that had some partial success, uh trying another different treatment class altogether if there is one available.
- 42:13SPEAKER_00: And uh always keep patient symptom management and outcomes in mind uh prior to making any changes to any long-term therapy.
- 42:21SPEAKER_00: And uh with that, we'll uh hand it over to Maggie to close out our discussion.
- 42:27SPEAKER_03: Excellent.
- 42:28SPEAKER_03: Um, thanks, Al.
- 42:29SPEAKER_03: I'll be speaking about the interprofessional team uh caring for patients with CIDP, um, as well as strategies uh for us to uh keep the patient um at the center of our care.
- 42:41SPEAKER_03: Um here my uh objectives.
- 42:46SPEAKER_03: Um of course, um, as I said, we try to keep the patient and their caregivers and their healthcare properties at the center of the care that we provide.
- 42:56SPEAKER_03: Um I always tell my patients that through their journey, they're always in the driver's seat.
- 43:00SPEAKER_03: We as providers can help them by you know making an accurate diagnosis, um, giving them about what that diagnosis means and prescribing um treatments and following them over time.
- 43:12SPEAKER_03: But just uh as importantly as all of that is, we can also arm them with the information and the data that they need to make these informed decisions about their care.
- 43:22SPEAKER_03: So here in this graphic, I get the patient at the center.
- 43:25SPEAKER_03: Um, I have the neurology physician and the neurology advanced practice provider, so a physician assistant or a nurse practitioner.
- 43:32SPEAKER_03: Um, we work pretty similarly to provide expert evaluation, workout, and diagnosis, um, discussing and deciding on treatment plans with patients, um and also serving as educational resources within our area of expertise.
- 43:47SPEAKER_03: We also have the uh patron um at the PCP, as well as other providers involved in the patient's care to provide their expertise on the patient and their other medical issues that may be important as we move forward.
- 44:00SPEAKER_03: And decide on treatment options and management long term.
- 44:06SPEAKER_03: We also rely on pharmacy rehab services, including PT and OT, as well as social work.
- 44:12SPEAKER_03: You know, PT and OT are extremely important in providing functional evaluation for our patients, discussing patients' mobility needs and goals of care, as well as helping patients choose assistive devices and adaptive equipment.
- 44:27SPEAKER_03: Pharmacy is invaluable in providing their expertise in pharmacology, dosing, contraindications, and interactions of treatments, also coordinating orders and shipment of medication and coordinating with infusion sites as well as nursing, as well as continuing to provide interval monitoring on treatment response and side effects.
- 44:49SPEAKER_03: And then finally, our social workers provide expertise in understanding the patient and caregiver through the social and cultural lens, explaining a patient's rights and the laws support people with disabilities, as well as helping patients and caregivers navigate towards resources for financial, social, employment, and well-being support.
- 45:11SPEAKER_03: So, what is this whole team like in reality?
- 45:14SPEAKER_03: We're all really kind of speaking to each other and communicating across multiple lines to care for our patients effectively.
- 45:22SPEAKER_03: And we also have further help in caring for a patient, administrative staff, clinical nursing, infusion nursing, mental health care biders, authorization departments, and more.
- 45:33SPEAKER_03: Now, I am very aware that depending on our clinic situation, not all of these resources will be available to us and to all of our patients.
- 45:42SPEAKER_03: I'm sure many of us as providers have had to put on a social worker hat or have had to take on administrative burden to care for our patients.
- 45:49SPEAKER_03: But our goal here is to create a comprehensive team that we can turn to each other's expertise to really support patients and caregivers in the best way that we can.
- 46:00SPEAKER_03: When I meet a patient for the first time, part of my job is to really get to know them as people.
- 46:06SPEAKER_03: When someone has experienced a functional decline, it can be very difficult for patients to even describe what weakness feels like or what numbness means to them.
- 46:15SPEAKER_03: I often think about patients who have painful conditions.
- 46:18SPEAKER_03: It's very easy to say, I have pain in this part of the body.
- 46:22SPEAKER_03: It can be very difficult to describe the absence of some kind of vital function like sensation or motor strength.
- 46:29SPEAKER_03: By getting to know a patient's home setup, their job, what assistive devices they're using, their caregiver support, it allows us to really glimpse into what their life is like and what it's like to walk in their shoes.
- 46:42SPEAKER_03: Not only to understand where there might be gaps in which we can help them, but also to understand what their strengths are and where where they seem to shine.
- 46:53SPEAKER_03: So, you know, getting to know their living environment, what kind of assistive devices they have in their house, banisters, um, what kind of responsibilities they have, um, do they care for pets, children, et cetera.
- 47:06SPEAKER_03: Kind of along that same line, um, putting together the patient picture, I like to think of this modified version of Braun von Brenner's ecological systems theory, um, which kind of looks at the multiple environments that surround a patient.
- 47:18SPEAKER_03: Um, of course, uh, we want to get to know the patient themselves, asking about their personal leaves, um, assessing what their health literacy might be, um, and understanding what their general mental health and well-being kind of looks like.
- 47:31SPEAKER_03: Just above that, we want to understand what their microenvironment is, uh, their lifestyle, their work, hobbies, relationships, responsibilities in their family unit, um, transportation, um, everything kind of uh immediately around the patient.
- 47:48SPEAKER_03: Above that, we have their EXO environment, which involves more extended communities.
- 47:53SPEAKER_03: So social and community relationships, spiritual and religious communities, the internet and mass media plays an important role here as patients come to clinic with certain expectation care, what they've read online and social media.
- 48:06SPEAKER_03: This can sometimes be helpful, sometimes can be a source of misinformation.
- 48:11SPEAKER_03: So it's important to acknowledge.
- 48:14SPEAKER_03: And then finally, we have the macro environment, which involves our economic systems that may provide opportunity or barriers to resources such as health insurance, protection from the law, like the Americans with Disabilities Act, as well as social and cultural norms such as ableism at the systemic and cultural level.
- 48:34SPEAKER_03: Um, as we've talked about throughout the series, there are a slew of objective measures we can use to gather objective data to determine a patient's overall level of function at baseline, and also to track their progress over time.
- 48:48SPEAKER_03: This includes the NCAT for sensory testing, the IRODS, which is a patient reported disability score, distal MRC SUM score, which is grading of the motor function on our exam, grip dynamometry, which provides us an objective measure of a patient's grip strength.
- 49:05SPEAKER_03: You know, while we always listen to what a patient's concerns are when they come into clinic, it's very important for us to really have these objective measures to track clinical improvement and clinical worsening so we can better track how a particular treatment might be affecting a patient.
- 49:22SPEAKER_03: I've also listed some other helpful tools to evaluate for uh quality of life and mental health.
- 49:28SPEAKER_03: Um we do have a quality of life measure in CIDP, but um, sometimes a PHQ 9 for depression or a GAD-7 can be very helpful in determining someone's mental health.
- 49:41SPEAKER_03: Um overall, um there's a uh there's a obviously a significant burden of disease in CIDP.
- 49:47SPEAKER_03: Uh this is a systemic review from the UK and Germany that really looked at the burden of disease in CIDP, and they found that the number one burden is the cost of drug.
- 49:59SPEAKER_03: We as providers have a responsibility to provide thorough and accurate medical documentation to prove to prove to insurance companies that patients need a CERN treatment.
- 50:08SPEAKER_03: Though this can be really arduous at times, long phone calls, um, you know, writing letters of medical necessity, um, this can really provide life-changing support for patients, not only because it allows them to access the treatment that they need, but it can also save the patient from a heavy financial burden.
- 50:26SPEAKER_03: Um we always think about the humanistic burden of CIDP as well.
- 50:30SPEAKER_03: Um, you know, there's a very high frequency of depressive symptoms in patients with CIDP compared to the general population, upwards of 50% higher.
- 50:40SPEAKER_03: There's little to no date on the rights of anxiety, uh, but I can say from anecdotal evidence in my own patients that anxiety can be quite high.
- 50:49SPEAKER_03: Um, if we think about the degree of disability associated with CIDP, I've had several patients express to me about you know not being able to take care of themselves if their caregiver wasn't around.
- 50:58SPEAKER_03: Or I had one patient with some particularly severe disease status tell me that he had fears about his ability to get out of a burning building.
- 51:05SPEAKER_03: Um, can be very scary stuff.
- 51:08SPEAKER_03: Not only that, um, but depressive symptoms can also contribute to or exacerbate physical symptoms of fatigue and pain.
- 51:16SPEAKER_03: Uh finally, um, I will leave you with some qualitative data that comes from Roberts and colleagues highlighting the patient and the provider experience of caring for patients with CIDP.
- 51:27SPEAKER_03: As we've already heard today, each patient can have very different experiences in their life from CIDP.
- 51:35SPEAKER_03: On the provider side, I also want to highlight that CIDP can be very difficult to treat.
- 51:40SPEAKER_03: It's very challenging to pull resources together, to coordinate care, to give patients the care that they deserve.
- 51:49SPEAKER_03: As we've seen through all of the presentations, um, you know, just by attending this course, you are a champion for folks living with CIDP care simply by expanding your knowledge base about this disease.
- 52:01SPEAKER_03: And I hope we can all walk away from it feeling a bit more knowledgeable and empowered to care for patients like this in our practice.
- 52:08SPEAKER_01: Thank you.
- 52:11SPEAKER_04: Thank you, Maggie.
- 52:12SPEAKER_04: This is an extremely important area of CIDP management that is often overlooked.
- 52:17SPEAKER_04: Uh, and now I would like to spend a few minutes thinking about the variety of guest case presentations we heard during the live echo sessions.
- 52:27SPEAKER_04: We're not going to re-present each case, but uh we are going to discuss some of the lessons that we all learned together.
- 52:34SPEAKER_04: So here are the five patients, uh very brief snapshots of each of them and five kind of core challenges and dilemmas that we encountered with each of them that we learned from.
- 52:47SPEAKER_04: For the first session, we had a 54-year-old man.
- 52:50SPEAKER_04: Uh he had what was considered typical CIDP, uh, if you remember back to how we described CID presentation, and yet they weren't responding to therapy.
- 53:01SPEAKER_04: And so the question that was posed to us by the presenting participant is is this patient really truly refractory, or is there something else going on with the way that they were treated that maybe precluded them from responding to the therapies that they were on?
- 53:18SPEAKER_04: The second session was a 65-year-old person uh who had Guillon Beret syndrome, the short, acute version of CIDP, a totally different disease, uh, but also is a demyelinating disease of the peripheral, uh the peripheral nervous system.
- 53:37SPEAKER_04: Uh usually it's a one-and-done deal.
- 53:40SPEAKER_04: You get Guillon Beret syndrome and then you get better, but this person didn't.
- 53:43SPEAKER_04: They kept progressing.
- 53:45SPEAKER_04: Uh and so the question with that patient was: do they have AIDP or do they have CIDP?
- 53:52SPEAKER_04: And what's the boundary between the two?
- 53:54SPEAKER_04: And how can you tell them apart?
- 53:57SPEAKER_04: The third session uh was a 48-year-old uh patient.
- 54:02SPEAKER_04: They uh they had they were on IVIG and we looked at their data and they had only one point of demyelination in their nerves.
- 54:12SPEAKER_04: We like to see at least two, if not multiple places uh of demyelination in order to call it a true polyneuropathy.
- 54:21SPEAKER_04: That's the P of CIDP.
- 54:23SPEAKER_04: And if you only have one uh point of demyelination, well, do they actually meet criteria for CIDP?
- 54:30SPEAKER_04: And does that affect whether and how we treat them?
- 54:33SPEAKER_04: The fourth session was a 75-year-old woman.
- 54:37SPEAKER_04: Uh the patient was experiencing ataxia, was unsteady on her feet, and she was found to have an anti-MAG IgM antibody that was very high.
- 54:47SPEAKER_04: And so the question was: is this CIDP?
- 54:50SPEAKER_04: Is this a variant of CIDP, and how do we change the way that we manage that patient?
- 54:55SPEAKER_04: Um, and the last session, session five, we were dealing with a 58-year-old person who had MADSAM, one of these other uh atypical variants, the asymmetric uh uh multifocal variant that uh Rachel described, um, but also had severe axonal loss.
- 55:14SPEAKER_04: And so it was a little bit ambiguous on the study whether we were dealing with pure demelinating disease, or was there also something bigger uh going on at the same time, like ALS or another neuron disease?
- 55:27SPEAKER_04: Um and so uh we thought of pulling out themes from uh each of these cases, uh recurrent themes that came up over and over again uh within each of these cases.
- 55:40SPEAKER_04: So the first theme that we talked about was uh earning the diagnosis before you escalate, right?
- 55:49SPEAKER_04: So it we noticed in a few, basically in all of them, you know, we it always came back to the same question of do they have CIDP?
- 55:58SPEAKER_04: Um do they meet what we call inclusion criteria, right?
- 56:02SPEAKER_04: Like do they have enough points of demyelination on their EMG?
- 56:05SPEAKER_04: Or conversely, do they have exclusion criteria that make us think about other diagnoses?
- 56:11SPEAKER_04: Um and there were a few mimics that we came up with, right?
- 56:14SPEAKER_04: We dealt with Guillain Buret syndrome, uh, which presents very much like CIDP on nerve conduction study, and yet they present much more quickly within four weeks, and they have reached the worst severity of their disease as opposed to CIDP, where they continue to decline over at least eight weeks.
- 56:32SPEAKER_04: It can be tricky to differentiate between the two, as we saw in case two.
- 56:37SPEAKER_04: Um and then with anti-MAG and dad's, right?
- 56:42SPEAKER_04: We we had a patient who had similar symptoms and yet they presented uh with this antibody.
- 56:50SPEAKER_04: Um, and so uh, which of course is associated with certain types of uh malignancy, uh, specifically in Waldenstrom's macroglobulinemia.
- 57:01SPEAKER_04: Um, and so it need makes us think more broadly about what else do they have, uh and could this be something not typical for that CIDP.
- 57:11SPEAKER_04: Um, and uh then of course we were dealing with someone who had mad SAM, this uh atypical variant that was picking off different nerves, um, and whether that person had ALS, and then um another patient who had who uh had functional overlay with their symptoms uh that made us uh rethink the original CIDP diagnosis.
- 57:37SPEAKER_04: So uh before we move on from this theme, does anyone have any uh thoughts about the keeping our differential open for all of these patients who came with us with purported CIDP?
- 57:50SPEAKER_00: I actually had a question for all of you ordering providers.
- 57:53SPEAKER_00: Um in a lot of these cases, you you you hear um you know the diagnosis isn't quite complete.
- 57:59SPEAKER_00: Uh hey, we gave them IG IVIG twice.
- 58:03SPEAKER_00: Um in and uh uh no surprise, not a great outcome.
- 58:08SPEAKER_00: Uh while you're working up a diagnosis for these patients, which could take a while, um what what do you what do you do to help with symptom management during that time?
- 58:18SPEAKER_00: That's a really good question, Alan, Rachel and Maggie.
- 58:20SPEAKER_04: What do you think?
- 58:20SPEAKER_04: You know, someone who's go undergoing a prolonged diagnosis, uh diagnostic uh process, do you start to treat them earlier or how do you approach that?
- 58:31SPEAKER_03: Yeah, I mean, uh I definitely am one to want to feel very confident in the diagnosis before beginning treatment, especially with, you know, what um we brought up with these like pair, even the perinodal um uh variants of this, you know, these are refractory to um some of the internal treatments.
- 58:51SPEAKER_03: And so kind of knowing right off the bat is the best.
- 58:53SPEAKER_03: That being said, you know, I'm very aware that it often takes a long time even to just get um access to a high quality um EMG test, and then of course get that test back to the ordering provider to interpret and make a make a decision.
- 59:08SPEAKER_03: Um in that time, my biggest concern for patients is a fall.
- 59:13SPEAKER_03: Um, so anything we can do to prevent a fall is something that I support, whether that means um escalating a patient's assistive device, getting them some extra help around the house, um, enrolling them in physical and occupational therapy to number one, maintain the function that they do have, um, and number two, learning some valuable strategies to help with safe mobility.
- 59:37SPEAKER_04: Beautiful.
- 59:38SPEAKER_04: Thank you, Maggie.
- 59:40SPEAKER_04: Um, yeah, let's move on to the second theme of uh electrodiagnostics.
- 59:47SPEAKER_04: Uh, and the theme here is to respect the conduction block and its pitfalls, right?
- 59:52SPEAKER_04: Uh so many times patients come with CIDP and you look at their studies that they've had and you question whether they met the criteria, and it's really important to re-emphasize that they a patient uh is diagnosed with definite CIDP if they have two or more uh points of demyelination on their nerve conduction study.
- 1:00:11SPEAKER_04: If they only have one, it's possible, but it's not definite.
- 1:00:15SPEAKER_04: Um, and when I perform a uh study on a patient, I keep testing more and more nerves until I find that second nerve because it's so important for their diagnosis and for their treatment.
- 1:00:27SPEAKER_04: Um, of course, uh there are so many pitfalls with nerve conduction studies, and that's uh that's really a huge part of uh technically uh a technically sound study.
- 1:00:40SPEAKER_04: There are so many artifactual mimics uh, including uh uh patients' BMI and how that uh affects the ability to get good uh uh good stimulation and recordings.
- 1:00:54SPEAKER_04: Uh, if the patient has a lot of edema on their uh in their body, a lot of swelling, then that can affect how well the study turns out.
- 1:01:02SPEAKER_04: And we have to be very careful in interpreting those studies.
- 1:01:05SPEAKER_04: And then uh and then what we call power, a reproducible conduction block uh can be the decisive clue toward treatable disease, even amid heavy axonal loss, right?
- 1:01:18SPEAKER_04: So the the problem can be that a patient has a lot of secondary axonal loss, and so it can be hard to see those demyelinating features if we diagnose them late.
- 1:01:28SPEAKER_04: And this is something that came up so many times in our discussions, and how frustrating it can be to have someone who has a lot of secondary a sonal loss making the diagnosis harder.
- 1:01:41SPEAKER_01: Did anyone have any more comments on that, the imp?
- 1:01:49SPEAKER_02: I would just say if there's any ambiguity, I really like to phone a friend and share with another neuromuscular person, have them look over the data if I'm at all unsure.
- 1:02:00SPEAKER_02: Um, because sometimes I'm anchoring or ignoring certain things.
- 1:02:05SPEAKER_02: And then I also um have found it's really helpful to um, if they're available, to go back and actually look at the waveforms.
- 1:02:15SPEAKER_02: Um, because I've had a couple of cases where I thought it was C, you know, it was thought to be CIDP, but then I looked at the waveforms and they looked so uniform and so kind of well organized rather than all spread out and temporal dispersion, and those ended up being um CMT cases instead.
- 1:02:40SPEAKER_02: So I think just going back to look at the data, if the data is not adequate, repeating the study and um having a friend also look at the data with you if you're just not sure.
- 1:02:52SPEAKER_04: Yeah, I totally agree with you.
- 1:02:53SPEAKER_04: Having that humility and and having those relationships with other people is so important.
- 1:02:58SPEAKER_04: And you're not alone by yourself in making these diagnoses.
- 1:03:03SPEAKER_04: Um the third theme that we talked about is the concept of a refractory patient, uh, someone who's had treatment and didn't respond.
- 1:03:13SPEAKER_04: And uh we uh the theme that we came up with is that refractory is a question, not a conclusion.
- 1:03:19SPEAKER_04: Um it could it could be that they are in fact refractory, but it could be that something else is going on.
- 1:03:25SPEAKER_04: For example, uh the patient has the wrong diagnosis um uh or has fixed damage, right?
- 1:03:34SPEAKER_04: And this goes back to that uh that concept of secondary axonal loss, right?
- 1:03:39SPEAKER_04: When someone is diagnosed late, then the inflammation gets deeper than just damaging the myelin and can damage the axons themselves.
- 1:03:48SPEAKER_04: And once you get to that stage, then then it's much harder to recover from their disability.
- 1:03:56SPEAKER_04: Um another theme that we saw in a couple of different patients was uh the uh the concept of an inadequate trial, right?
- 1:04:06SPEAKER_04: Uh we might be doing a good job at controlling the immune system, but then we have to keep in mind that once we're controlling the immune system, we need to give them time to re-myelinate before we see improvement.
- 1:04:18SPEAKER_04: And so it can be a few months in this slowly developing and slowly resolving condition before we see an improvement in their clinical uh uh picture.
- 1:04:29SPEAKER_04: Uh, and so a mistake that many providers make is by trying someone on IVIG or even a Tuxamag or whatever it is, only for a few weeks or a couple of months and not giving them time to heal.
- 1:04:41SPEAKER_04: Um, and then number three uh that we did see in a patient uh was underdosing, making sure that uh that the highest possible dose of IVIG, for example, is given before we consider it a failure.
- 1:04:56SPEAKER_04: Um so you know, before you escalate, recheck the diagnosis, make sure you got the dosage right, or tried the highest possible dose or frequency of a drug, and then make sure that you gave it enough time.
- 1:05:10SPEAKER_04: Um did anyone have anything to add to that theme?
- 1:05:15SPEAKER_00: I think you're right.
- 1:05:16SPEAKER_00: That was a recurring theme in almost every every case we had.
- 1:05:20SPEAKER_00: It was the the diagnosis wasn't quite quite right.
- 1:05:23SPEAKER_00: Uh, we gave them one dose of IVIG.
- 1:05:25SPEAKER_00: They either did or did not feel better, and then then nothing else happened.
- 1:05:29SPEAKER_00: Um just just a really strong recurring uh theme throughout all our cases.
- 1:05:34SPEAKER_04: Yeah, I think uh uh as as physicians or as providers of of all you know of all types, you know, we we like to do things, right?
- 1:05:44SPEAKER_04: And we it feels helpless to sit there and watch.
- 1:05:47SPEAKER_04: Um and so resisting that uh that inclination to change things too quickly is really important, and it's something that we saw in a few cases.
- 1:05:58SPEAKER_04: Um the four Fourth theme to optimize the regimen, not just the drug.
- 1:06:05SPEAKER_04: So we had a couple of cases where, for example, the dose, a patient was given the IVIG loading dose of two grams per kilogram, but then some of those patients need uh higher maintenance doses or tighter windows between cycles.
- 1:06:24SPEAKER_04: Um and so uh and so adding to it before switching is important to try.
- 1:06:30SPEAKER_04: Um, also the route of administration can um can be important.
- 1:06:36SPEAKER_04: We had a case where a patient wasn't tolerating IV IG, but remembering that subcutaneous Ig is another option was uh integral for that patient.
- 1:06:46SPEAKER_04: Um and that can help, especially in patients who don't have close access to a large enough medical center where traveling distance is a huge uh uh barrier to treatment.
- 1:06:59SPEAKER_04: Uh and then uh escalating care, um, you know, for example, escalating to Rituximab for truly refractory disease, um, and coordinating with neuromuscular expertise to kind of know when to make that decision.
- 1:07:14SPEAKER_04: Um so uh so so that can be the answer in the end of the day, but thinking about what they're on and how to optimize what they're on already before jumping to a stronger agent.
- 1:07:27SPEAKER_04: Um so yeah, any any comments for that that fourth theme?
- 1:07:34SPEAKER_04: We sort of addressed that with the third theme a little bit, but um, so a little bit overlapping, but but yeah uh you know, thinking about optimizing before.
- 1:07:44SPEAKER_04: Um and then we can move on to the fifth theme, uh, which is uh monitoring.
- 1:07:51SPEAKER_04: So uh how do we monitor these patients and how do we measure these patients objectively uh and match that measure to the patient, right?
- 1:07:59SPEAKER_04: So uh as we said before, Rachel went into the different types of uh validated uh um measuring tools that we have the MRC grade, INCAT, IRODs, grip dynamometry, um, and so uh having all of those at your disposal disposal so that you can watch the patient uh each time you see them and see if they're improving or whether they're staying stable or worsening.
- 1:08:28SPEAKER_04: Um and it's important when you're doing that to match the uh tool that you're using to the phenotype, right?
- 1:08:35SPEAKER_04: If you're using dynamometry of grip strength uh in order to judge the improvement of someone who has mostly lower extremity uh symptoms, well, that's a mismatch between your measuring tool that you're using and the presentation of that patient.
- 1:08:51SPEAKER_04: And so it's really important to find the right measuring tool that works for the patient in front of you.
- 1:08:56SPEAKER_04: Um resolving discordance, uh, you know, a patient can uh can report feeling weaker or not feeling better, and then they come in and their examination is actually objectively improved when we do confrontational MRC grading on their on them.
- 1:09:12SPEAKER_04: And uh and so um so that uh internal measure of how a patient is feeling can be discrepant with our observations when we see them in the clinic.
- 1:09:24SPEAKER_04: Um, and that can uh that can happen to a lot of patients.
- 1:09:29SPEAKER_04: Um and then uh you know nerve conduction studies and when to repeat them is a whole other question of you know, how do we track nerve conduction studies over time and how do we use that?
- 1:09:44SPEAKER_04: Um and we discussed that in one of our cases as well.
- 1:09:47SPEAKER_04: Um and really the the essence is you know to track their function and not how they're feeling, uh, re-examine their muscles every time you come in and their strength, right?
- 1:09:58SPEAKER_04: In order to kind of get try to get as objective measures as possible.
- 1:10:02SPEAKER_04: Anyone have any um anything that they want to say about this theme?
- 1:10:10SPEAKER_03: I think this uh theme can also really help with the question of like a refractory case.
- 1:10:14SPEAKER_03: Um, you know, from the patient perspective, they may not notice subtle changes.
- 1:10:19SPEAKER_03: Patients feel very tired, patients feel very weak.
- 1:10:22SPEAKER_03: And so there are situations where they come in and they don't feel better or they or they actually feel worse.
- 1:10:27SPEAKER_03: And and the only way that we can really track any response, improvement or worsening is with these objective measurements.
- 1:10:34SPEAKER_03: And in those situations, it's very hard to um, you know, explain those to the patients.
- 1:10:39SPEAKER_03: Um, you know, we certainly want to validate the way that they're feeling, um, but we also want to make it very clear to them that we're tracking this in any other ways besides their patient report to make the most informed decision about their care.
- 1:10:53SPEAKER_04: Yeah, you know, it's really important to remember that they're living their own lives every day, and we see them once every few months.
- 1:11:00SPEAKER_04: And so we have on one hand, it means that we don't know them as intimately as they know their own bodies, but conversely, we have the ability to have that step back and say, Oh, I saw you three months ago and I see you now.
- 1:11:15SPEAKER_04: You actually have improved, even though you don't feel it day to day.
- 1:11:19SPEAKER_04: Right.
- 1:11:20SPEAKER_04: Um then uh the last theme, uh, the nerve belongs to a patient.
- 1:11:26SPEAKER_04: Treat the whole context, whole patient care was the last theme that we uh that we had.
- 1:11:32SPEAKER_04: And so thinking about access, how far does the patient have to travel in order to get the treatment that we want them to get?
- 1:11:38SPEAKER_04: Can they qualify for home infusion and is their home safe to do that?
- 1:11:43SPEAKER_04: Uh safety at home, are they living alone?
- 1:11:45SPEAKER_04: Uh how do they get up their stairs and into the bathroom?
- 1:11:48SPEAKER_04: Do they have AFOs or other uh modifications that help them uh with their ambulation?
- 1:11:56SPEAKER_04: Uh who do they have on their team?
- 1:11:58SPEAKER_04: Do they have physical therapy and occupational therapy uh set up?
- 1:12:02SPEAKER_04: Oftentimes the answer is no, and we have to we've had to advise a couple of the cases that came uh in front of us.
- 1:12:10SPEAKER_04: Why don't you just have them do PT while you're treating them?
- 1:12:13SPEAKER_04: That's gonna help them improve.
- 1:12:14SPEAKER_04: Um, social work, swallowing, uh pulmonar pulmonology as needed.
- 1:12:19SPEAKER_04: Uh and then partnership, right?
- 1:12:22SPEAKER_04: Uh having a shared decision-making process with the patient.
- 1:12:27SPEAKER_04: They always should be in charge and they always have options.
- 1:12:30SPEAKER_04: And we need to remember as providers to not approach them paternalistically and and remember to have a discussion of like, well, do you want to change what you're doing?
- 1:12:40SPEAKER_04: In the end, this is your body, and I can advise you.
- 1:12:43SPEAKER_01: Um, any last thoughts about whole patient care?
- 1:12:52SPEAKER_01: And I know that Maggie really uh touched on that in her talk, uh, in their talk.
- 1:12:57SPEAKER_03: Um I think a helpful tip is just always to ask what the patient is most concerned about or what their goals are for the particular visit.
- 1:13:06SPEAKER_03: You know, you may see them walking back from the waiting room and you're like, oh gosh, they look so unstable.
- 1:13:11SPEAKER_03: And their biggest concern today is pain management.
- 1:13:14SPEAKER_03: And so, you know, you can address both, but making sure that like you're addressing what's most important to the patient is kind of what I try to focus on, you know, my efforts towards speaking to the patient.
- 1:13:25SPEAKER_01: And, you know, we can do the rest behind the scenes.
- 1:13:30SPEAKER_02: I would also add that just talking to patients about what their day-to-day lives are like, um, and what activities end up being the most difficult and stressful for them because of their symptoms is a great way to find out um how people are doing, how you can support them best.
- 1:13:51SPEAKER_04: So in conclusion, I think our cases can be summarized into this framework.
- 1:13:59SPEAKER_04: Uh number one, earn the diagnosis, make sure that they have all the inclusion criteria, enough points of demyelination on their nerve conduction study, and meet the exclusion criteria, make sure they're not we're not dealing with a different disease altogether.
- 1:14:17SPEAKER_04: Uh number two, trust their reproducible electrodiagnosis and respect the pitfalls, right?
- 1:14:23SPEAKER_04: Make sure that you analyze that nerve conduction study, and if it's hard, phone a friend and you can interpret it together.
- 1:14:30SPEAKER_04: Uh number three, read refractory as three questions, right?
- 1:14:35SPEAKER_04: If a patient isn't responding to therapy, are you sure you have the right diagnosis?
- 1:14:40SPEAKER_04: Are you sure you have the right dose?
- 1:14:41SPEAKER_04: And have they been on it long enough to have seen improvement?
- 1:14:47SPEAKER_04: Number four, make sure that you individualize the dose, the root and escalation, right?
- 1:14:52SPEAKER_04: Make sure that you don't get hooked on giving them IVIG every four weeks.
- 1:14:56SPEAKER_04: And if they need it more frequently or at a higher dose, you know, everyone's different.
- 1:15:01SPEAKER_04: Uh, and as we see, it's an umbrella of diagnoses.
- 1:15:04SPEAKER_04: Everyone responds to a different amount.
- 1:15:06SPEAKER_04: Um and finally, uh, number five, measure their function objectively and treat the whole patient.
- 1:15:14SPEAKER_04: So uh, you know, as we discussed, there's so many uh factors to their disease, and in the end, um, what we want to do is let every patient live the best life they can.
- 1:15:28SPEAKER_04: Uh and so there are a lot of ways to achieve that.
- 1:15:32SPEAKER_04: One through medical treatment, but through so many other avenues that we discussed.
- 1:15:37SPEAKER_04: Um it's about time to wrap up this special enduring edition of our CIDP series.
- 1:15:45SPEAKER_04: I want to thank our stellar faculty, uh Maggie and Al and Rachel, for being part of this special edition as well as the live series, and thank you, our audience, for your participation.
- 1:15:58SPEAKER_04: We had amazing live participation.
- 1:16:01SPEAKER_04: Uh and to receive CME and CE credit, please complete the post test and evaluation.
- 1:16:08SPEAKER_04: I hope you all have a great day.